Class ITerminatedD-1052-2014
Drug recall · February 5, 2014
Sermorelin/GHRP-6 recall
Why: Lack of Assurance of Sterility: The recall is being initiated due to a lack of sterility assurance and concerns associated with the quality control processes identified during an FDA inspection.
Class I: a reasonable chance the product could cause serious harm or death.
The recall
- Product
Sermorelin/GHRP-6, 3 mg/3 mg, 5 mL vial, Stock # 21740, Compounded by NuVision Pharmacy, Dallas, TX 75244
- Lots / codes
Lot #:N10172012@11, Exp 10/17/2013
- Quantity
- 122 vials
- Company
- NuVision Pharmacy, Inc., Dallas, TX
- Distribution
- Nationwide
- Initiated
- April 15, 2013 · Voluntary: Firm initiated
- Classified
- January 30, 2014
- Reported
- February 5, 2014
- Ended
- February 8, 2017
- How notified
- Press Release
If you have this product
- Check the lot number on your package against the lots above. Only those lots are recalled.
- Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
- Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
- Return or dispose of recalled product as the company or your pharmacy advises.
Recalled with it (same recall event)
Questions about this recall
No comments yet. Questions, tips, what worked for you - start the conversation.